The potential for
tumor vascular-targeting by using the
tubulin destabilizing agent disodium
combretastatin A-4 3-0-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established
tumor vasculature, leading to the development of extensive
tumor cell
necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22
carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled
iodoantipyrine, and quantitative autoradiography was used to measure spatial heterogeneity of blood flow in
tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at 1 and 6 h
after treatment and a very large decrease in
tumor blood flow, which-by 6 h-was reduced approximately 100-fold. The spleen was the most affected normal tissue with a 7-fold reduction in blood flow at 6 h. Calculations of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quantitative autoradiography showed that CA-4-P increased the spatial heterogeneity in
tumor blood flow. The
drug affected peripheral
tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the
nitric oxide synthase inhibitor,
N(omega)-nitro-L-arginine methyl ester, potentiated the effect of CA-4-P in
tumor tissue. The combination increased
tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of
nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in
tumor vascular resistance could also be obtained in isolated
tumor perfusions using a cell-free perfusate, although the changes were much less than those observed in vivo. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and
combretastatin A-4 (CA-4) was more efficient in
tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a
tumor vascular-targeting agent.